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Cell-penetrating peptides (CPPs), such as nona-argi-
nine (9R), poorly translocate siRNA into cells. Our
studies demonstrate that attaching 9R to ligands
that bind cell surface receptors quantitatively in-
creases siRNA uptake and importantly, allows func-
tional delivery of complexed siRNA. The mechanism
involved accumulation of ligand-9R:siRNA micropar-
ticles on the cell membrane, which induced transient
membrane inversion at the site of ligand-9R binding
and rapid siRNA translocation into the cytoplasm.
siRNA release also occurred late after endocytosis
when the ligand was attached to the L isoform of
9R, but not the protease-resistant 9DR, prolonging
mRNA knockdown. This critically depended on en-
dosomal proteolytic activity, implying that partial
CPP degradation is required for endosome-to-
cytosol translocation. The data demonstrate that
ligand attachment renders simple polycationic
CPPs effective for siRNA delivery by restoring their
intrinsic property of translocation.
INTRODUCTION
Cell-penetrating peptides (CPPs) can translocate into cells in an
autonomous and receptor-independent manner with low cyto-
toxicity and immunogenicity (reviewed in Fonseca et al., 2009;
Gump and Dowdy, 2007). Many primary cell membranes that
constitute an impermeable barrier to reagents that easily trans-
fect cell lines are permeable to CPPs. CPPs are thus promising
delivery vehicles for a vast range of biologically functional cargo
(Du et al., 2011; Eguchi and Dowdy, 2009; El-Sayed et al., 2009;
Fawell et al., 1994; Jones et al., 2005; Looi et al., 2011; Schwarze
et al., 1999). HowCPPs enter cells and access the cytoplasm are
areas of active investigation (Erazo-Oliveras et al., 2012;
Schwarze and Dowdy, 2000). Depending on CPP composition,
concentration, cell type, and the experimental conditions used,50 Chemistry & Biology 22, 50–62, January 22, 2015 ª2015 Elsevierenergy-independent as well as endocytic pathways are involved
in CPP uptake and translocation (Duchardt et al., 2007; Fischer
et al., 2004; Fretz et al., 2007; Futaki et al., 2007; Hirose et al.,
2012; Madani et al., 2011; Payne et al., 2007; Rothbard et al.,
2005; Verdurmen et al., 2011; Wadia et al., 2004). Cationic argi-
nine-rich CPPs (R-CPPs) can noncovalently complex with small
interfering RNA (siRNA). Despite their typical ability to effectively
translocate biological macromolecules, R-CPPs are poor vehi-
cles for cytoplasmic delivery of siRNA. For measurable mRNA
knockdown, a huge excess of CPP molecules and high siRNA
concentrations (above the therapeutic range) and/or association
with reagents that disrupt endosomes are generally necessary
(Akita et al., 2010; Cantini et al., 2013; El-Sayed et al., 2009; En-
doh and Ohtsuki, 2009; Erazo-Oliveras et al., 2012; Lee et al.,
2008; Margus et al., 2012; van Asbeck et al., 2013; Zhang
et al., 2014). Imaging studies reveal the vast majority of CPP-
siRNA complexes trapped for extended periods in intracellular
vesicles with little or no cytoplasmic localization (Al-Taei et al.,
2006; El-Sayed et al., 2009; Erazo-Oliveras et al., 2012; Fretz
et al., 2007; Fuchs and Raines, 2004; Maiolo et al., 2005; Verdur-
men et al., 2011). R-CPPs have thus been used more as cofor-
mulants for enhancing transfection efficiencies, rather than as
primary components of synthetic siRNA delivery systems (Be-
loor et al., 2012; Cheng and Saltzman, 2011; Kim et al., 2010;
Margus et al., 2012; Nakamura et al., 2007).
We previously used the homopolymeric R-CPP nona-D-argi-
nine (9DR) for delivering electrostatically complexed siRNA by
covalently coupling 9DR to peptide/protein ligands that bind
cell-surface receptors (Kumar et al., 2007, 2008; Subramanya
et al., 2010). This ‘‘ligand-9R’’ approach not only targeted siRNA
specifically to cells bearing a receptor for the ligand, but also
induced potent gene silencing (Kumar et al., 2007, 2008). This
raised the question of how ligand attachment to 9R elicited func-
tional siRNA delivery, which has been the formidable challenge
to realizing the potential of siRNA therapeutics.
By correlating live-cell microscopy observations of siRNA
localization with measurements of siRNA bioactivity, we deter-
mined that whereas native 9R peptides (D and L isoforms) lost
their intrinsic ability to translocate upon siRNA complexation,
ligand-9R enabled cytoplasmic siRNA delivery (1) at the cell sur-
face by tethering microparticles on the plasma membrane in aLtd All rights reserved
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at the site of binding and rapid siRNA translocation; and (2)
from late endosomes using mechanisms that required endoso-
mal protease activity. The latter occurred only when the L iso-
form of 9R was used (ligand-9LR) and prolonged the dynamics
of gene silencing. Our results demonstrate that attachment to
ligands restores the fundamental property of CPP translocation,
eliciting effective delivery of siRNA.
RESULTS
9R Peptides Effectively Translocate Covalently
Attached Molecules but Not siRNA
In preliminary analyses of 9R translocation, the murine neuro-
blastoma cell line, Neuro2a, was exposed to Alexa488
(700 Da)-labeled 9DR or 9LR. Both peptides became cell asso-
ciated within 1 hr and a significantly higher uptake occurred with
9DR by 24 hr (Figure 1A) in terms of cell numbers and levels per
cell (Figure 1B, left and right, respectively). 9D/LR peptides also
translocated covalently conjugated recombinant GFP protein
(Figure 1C) and 9DR-GFP again accumulated to higher levels
at 24 hr (Figure 1D). Thus, covalent attachment of low molecular
weight or macromolecular cargo to 9R did not hamper cellular
uptake and 9DR displayed better translocation properties,
concurring with previous reports documenting superior cell-
penetrating activity of protease-resistant D-oligomers of arginine
(Kamei et al., 2008; Tu¨nnemann et al., 2008; Verdurmen et al.,
2011; Wender et al., 2000).
We next evaluated siRNA delivery by the cationic 9R peptide.
siRNA was effectively complexed by 9D/LR peptides forming
nanoparticles at peptide molar excesses of 10 and above (Fig-
ures S1A and S1B available online). However, transfection effi-
ciencies in Neuro2A cells were relatively poor and comparable
with the commercial transfection reagent Lipofectamine 2000
only at peptide:siRNA molar ratios R20:1 (Figures 1E and 1F).
GFP siRNA complexed to 9DR or 9LR did not silence GFP
expression in Neuro2a cells stably expressing the protein (Fig-
ures 1G and 1H). Therefore, 9R peptides poorly translocated
siRNA, unless used at a high molar excess (>50; Cantini et al.,
2013; Wang et al., 2007; Zhang et al., 2014).
9R Peptides Effectively Translocate siRNA when
Attached to a Cell-Binding Ligand
RVG, a 32-amino acid peptide derived from the Rabies virus
glycoprotein, binds nicotinic acetylcholine receptor (nAchR)
subunits and directs tropism toward receptor-bearing cells (Ku-
mar et al., 2007, 2008; Subramanya et al., 2010). When chimeric
with RVG, both 9R peptides bound siRNA and formed nanopar-
ticles (Figures S1C and S1D). Fusing 9R to another targeting
ligand, a single chain antibody, also did not significantly change
siRNA binding (data discussed below, Figures S1E and S1F).
Attachment of 9R to RVG dramatically enhanced uptake of
complexed siRNA in Neuro2a cells that express nAchR. Mean
fluorescence intensities (MFIs) were at least 2 logs higher 24 hr
following treatment (627 ± 124 and 1,527 ± 121 for RVG-9DR
and RVG-9LR, respectively [Figures 2A and 2B] compared to
6.7 ± 0.2 and 11.2 ± 1.4 for 9D/LR peptides at a 10:1 peptide:
siRNA ratio and 81 ± 0.66 with Lipofectamine 2000 [Figures
1E and 1F]). Importantly, RVG-9R:siRNA complexes effectivelyChemistry & Biology 22,silenced gene expression (Figures 2C, 2D, and S2) and here,
siRNA complexed to RVG-9LR silenced GFP better than RVG-
9DR and Lipofectamine 2000 (GFP-negative cells increased by
69.8 ± 2.7%, 42.1 ± 23.4% and 46.6 ± 19%, respectively [Fig-
ure 2D]). Thus, attachment of 9R to RVG likely enabled delivery
of siRNA to cytoplasm, which is key for RNA interference
(RNAi; Wei et al., 2011).
Coupling 9D/LR to another targeting ligand—a murine single
chain antibody scFvCD7 (Figures S1E and S1F) that binds the
CD7 molecule expressed on human T cells (Kumar et al.,
2008)—similarly enhanced siRNA uptake into the human T cell
line Jurkat (MFIs of 70.83 ± 26.05 and 104.6 ± 12.27 with
scFvCD7-9D/LR versus 18.60 ± 0.82 and 20.97 ± 0.99 for 9D/
LR and 3.81 ± 0.17 for Lipofectamine 2000; Figure 2E) and
appreciably silenced target CD4 mRNA levels as early as 4 hr
after treatment (64.5 ± 5.9% and 65.6 ± 3.6%with siCD4 in com-
parison to siLuc complexed with scFvCD7-9D/LR; Figure 2F).
Native 9D/LR peptides as well as Lipofectamine 2000 failed to
elicit target mRNA knockdown, in keeping with the highly resis-
tant nature of Jurkat cells to transfection. Thus, the observations
were not unique to RVG-9R but are a feature of the ligand-9R de-
livery platform. Attachment to a cell-binding ligand therefore
transforms 9R, a poor siRNA delivery agent, into a highly effec-
tive siRNA carrier for gene silencing, even in cells resistant to
conventional transfection methods.
RVG-9R Mediates Cytoplasmic Translocation of siRNA
The effective siRNA uptake and gene knockdown attained with
RVG-9R, unlike with 9R peptides, suggests a trafficking pathway
that ultimately resulted in cytoplasmic siRNA delivery. Two
mechanisms are implicated in the cellular entry of CPPs and their
attached cargo: energy-independent direct translocation at CPP
concentrations of R10 mM (Nakamura et al., 2007; Rothbard
et al., 2005; Rydstro¨m et al., 2011) and endocytosis mecha-
nisms, such as macropinocytosis, at %5 mM (Duchardt et al.,
2007; Fischer et al., 2004; Madani et al., 2011; Payne et al.,
2007; Verdurmen et al., 2011; Wadia et al., 2004). The final con-
centration of the RVG-9R peptides in siRNA translocation exper-
iments ranged between 2 and 5 mM, which is at or below the
threshold value that elicits direct translocation into the cytosol.
The requirement of a ligand for cellular entry was indicative of
receptor binding and therefore receptor-mediated endocytosis.
Incubation at 4C reduced, but did not abolish, cellular uptake
of RVG-9R:siFITC complexes, indicating that temperature-inde-
pendent mechanisms also play a role in ligand:9R uptake
(Figure S3A).
Time-lapse imaging of Neuro2A cells exposed to RVG-9R:
siFITC complexes revealedmultiple small particle-like structures
1–3 mm in diameter accumulating and tethering on the plasma
membrane (Figure 3A; see also Movies S1 and S2). Strong fluo-
rescence (green) spread throughout the cytoplasm after influx of
these particles, typically by about 20 min after treatment (26.4 ±
2.7 min and 22.1 ± 2.8 min with RVG-9DR/LR respectively, Fig-
ures 3A and 3B). This translated to significant target mRNA
knockdown within 1 hr after transfection, confirming early deliv-
ery of functional siRNA (Figure 3C). Some siRNA (red) colocal-
ized with early EEA1+ endosomes (green, Figure 3D); however,
late endosomes (labeled with the red LysoTracker dye) were
completely devoid of siRNA (green, Figure 3A) at these early50–62, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 51
Figure 1. 9DR and 9LR Ineffectively Translocate siRNA
(A and B) Flow cytometric analysis of Neuro2a cells after exposure to 10 mM 9D/LR-A488. Representative histograms are shown in (A), and cumulative data in (B),
depicting transfection efficiencies as percent cells (left) and mean fluorescence intensities (MFI, right). Filled histograms in (A) represent untreated cells. In (B),
cells were scored as positive for uptake using the marker gate (black line) depicted in (A).
(C) Live confocal microscopy of Neuro2a cells at 24 hr after incubation with 9D/LR-GFP conjugates. The nucleus is stained with Hoechst 33342 (blue).
(D) Quantification of GFP fluorescence intensities in 9D/LR-GFP treated Neuro2A cells using the Volocity software (sample size, 50 cells).
(E and F) Flow cytometric analysis of Neuro2a cells 24 hr after exposure to 9D/LR complexed with FITC-labeled siRNA (siFITC). Representative histograms for a
peptide:siRNA molar ratio of 25:1 are shown in (E), and cumulative data depicting siRNA transfection efficiencies as percent cells (left) and average MFI (right) in
(F). The filled histograms in (E) correspond to cells transfected with siFITC alone. In (F), cells were scored as positive for uptake using the marker gate (black line)
depicted in (E).
(G and H) Flow cytometric analysis of Neuro2a cells expressing GFP 72 hr after exposure to 9D/LR complexed with siGFP (100 pmol siRNA, 10:1 peptide:siRNA).
Representative histograms are shown in (G). The filled histograms correspond to cells transfected with siGFP alone. Cumulative data in (H) depict GFP silencing
as percent increase in GFP-negative cells compared to cells treated with siRNA alone scored using the solid marker gate in (E) (left) and fold decrease in GFPMFI
scored using the dashed marker gate in (E) (right).
(E–H) LMN, Lipofectamine 2000; siLuc and siGFP, siRNAs targeting firefly luciferase and GFPmRNA. (B, D, F, H) error bars indicate SEM. (B, F, H) *p < 0.05, **p <
0.01, ***p < 0.001; ns, nonsignificant. See also Figure S1.
Chemistry & Biology
Ligands Potentiate CPP-Mediated siRNA Delivery
52 Chemistry & Biology 22, 50–62, January 22, 2015 ª2015 Elsevier Ltd All rights reserved
Figure 2. 9D/LR Effectively Translocate
siRNA when Attached to a Cell-Binding
Ligand
(A and B) Flow cytometric analysis of Neuro2a cells
24 hr after exposure to RVG-9D/LR:siFITC.
Representative histograms at a peptide:siRNA ra-
tio of 10:1 are shown in (A), and cumulative data for
siRNA transfection efficiencies depicted as
percent cells (left) and MFI (right) in (B). In (B), cells
were scored as positive for uptake using the
marker gate (black line) depicted in (A).
(C and D) Flow cytometric analysis of Neuro2a cells
expressing GFP 72 hr after exposure to siGFP
complexedwithRVG-9D/LR (100pmol siRNA, 10:1
peptide:siRNA). Representative histograms are
shown in (C). Cumulative data for GFP silencing in
(D) depict percent increase in GFP-negative cells
(left) and fold decrease inGFPMFI (right) compared
to cells treated with siRNA alone scored using the
solid and dashedmarker gates, respectively, in (C).
(E) Flow cytometric analysis of Jurkat cells 24 hr
after exposure to siFITC complexed to the indi-
cated reagents.
(F) QPCR analysis of CD4 mRNA levels in Jurkat
cells 4 hr after treatment with scFvCD7-9D/
LR:siCD4 (200 pmol siRNA, 10:1 protein:siRNA).
In (A), (C), and (E), the filled histograms correspond
to cells transfected with siRNA alone. LMN, Lip-
ofectamine 2000; siLuc, siGFP, and siCD4 are
siRNAs targeting firefly luciferase, GFP, and hu-
man CD4 mRNAs, respectively. (D and F) Error
bars indicate SEM. (B, D, F) *p < 0.05, **p < 0.01.
See also Figures S1 and S2.
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chalasin D or the dynamin inhibitor dynasore did not significantly
affect cytoplasmic siRNA fluorescence at 1 hr after exposure to
peptide-siRNA complexes (green, Figure 3E), although it
reduced intracellular punctate fluorescence in cells exposed to
transferrin (red, Figure S3B). These data indicate that RVG-9R:
siRNA delivery to the cytoplasm occurs rapidly in an actin/dyna-
min-independent manner across the plasma membrane or from
very early endosomes.
RVG-9R:siRNA Complexes Induce Topical Membrane
Inversion
Because 9D/LR:siRNA complexes did not associate with the
plasma membrane for longer times (Figure 3A extreme right,
no microparticles seen by 22 min) or lead to vesicular or cyto-
plasmic fluorescence (see Movies S3 and S4), ligand-receptor
binding appeared critical for initiating cellular entry of RVG-
9R:siRNA complexes. Indeed, pretreatment of Neuro2A with
a-bungarotoxin, a competitive inhibitor of RVG (Kumar et al.,
2007) significantly reduced uptake of RVG-9LR:siFITC (Fig-
ure 4A). We investigated if plasma membrane inversion, a mech-
anism identified in the energy-independent entry of 9R into cells
(Hirose et al., 2012), occurred at the site of ligand-9R/siRNA-re-
ceptor binding. Exposure of cells treated with RVG-9LR:siRNA
complexes resulted in strong costaining with Alexa568-labeled
annexin V within 30 min indicating membrane inversion (Figures
4B and 4C). Strong annexin V positivity persisted for up to and
beyond 2 hr in cells treated with RVG9D/LR:siRNA (Figure 4C);
surprisingly however, this did not result in a loss of membraneChemistry & Biology 22,integrity or cell cytotoxicity (measured by a lack of lactate dehy-
drogenase in culture medium and the Alamar blue cytotoxicity
assay respectively, data not shown). Accordingly, most cells
were no longer annexin V positive at 24 hr, but continued to
remain positive for siFITC, signifying membrane inversion was
temporary (Figure 4C). Annexin V signals were not detected on
cells treated with RVG peptide lacking 9LR or 9LR:siRNA com-
plexes, indicating that ligand attachment as well as the presence
of the CPP was essential for membrane inversion in the context
of complexed siRNA. Cells exposed to RVG-9LR alone were also
positive for annexin V, albeit to a lesser extent, indicating that
polyplex formation in the presence of siRNA increased exposure
of the inner membrane.
We next resorted to generating siRNA complexes in situ by
adding RVG-9R to Neuro2A cells in medium containing siRNA
rather than using preformed siRNA complexes, because the ki-
netics of membrane inversion with the latter were too rapid to be
captured in movie format. This strategy enabled visualization of
peptide:siRNA complexes assembling at a reduced rate
(1–2 hr) and also significantly reduced subsequent cyto-
plasmic fluorescence. For these experiments, we restricted
our investigations to RVG-9LR because the two peptides ap-
peared to display comparable dynamics of cellular entry and
similarly induced annexin, at least at early time points. Annexin
V staining (red) was highly localized to the site of RVG-9LR:si-
FITC binding (green), and appeared to occur even from
vesicle-like structures within the cell (Figure 4D, arrows; see
also Movie S5). No annexin V-staining was detected in the pres-
ence of a-bungarotoxin, indicating that ligand-receptor binding50–62, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 53
Figure 3. Early Cytoplasmic Entry of RVG-9R:siRNA Is Actin/Dynamin Independent
(A) Time-lapse images of Neuro 2A cells pre-stained with LysoTracker (red) acquired within 1 hr of exposure to peptide:siFITC complexes. Fluorescent and
differential interference contrast images in the same fields were merged. Time 0: images captured immediately after the addition of siRNA complexes.
(B) Quantification of time (minutes) to appearance of cytoplasmic fluorescence in Neuro2a cells treated with RVG-9D/LR:siFITC. Each dot represents a cell. Mean
and SD are depicted.
(legend continued on next page)
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Figure 4. Ligand-9R Induces Localized
Membrane Inversion
(A) Flow cytometric analysis of Neuro2a cells
pretreated with A568-labeled a-bungarotoxin (BTX)
30 min after exposure to RVG-9LR:siFITC
(100 pmol siRNA, 10:1 peptide:siRNA). Numbers in
red and green represent cell percentages positive
for BTX and siRNA, respectively.
(B) Live confocal microscopy of Neuro2a cells
30 min after exposure to RVG9D/LR:siFITC (green)
and Alexa568-labeled annexin V (red). Fluorescent
images in the same fields were merged.
(C) Flow cytometric analysis of Neuro2a cells
treated with A568-labeled annexin V after exposure
to the indicated reagents for the indicated times.
Numbers in red and green represent cell percent-
ages positive for annexin V and siFITC, respec-
tively.
(D) Time-lapse images of Neuro2A cells pre-incu-
bated with A568-labeled annexin V and siFITC at
the indicated times after exposure to RVG-9LR.
Fluorescent and DIC images in the same fields
were merged. Arrows indicate sites of peptide:
siRNA binding.
See also Movie S5.
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the mechanism even with siRNA complexes formed in situ (data
not shown). These observations provide evidence that ligand-9R
induces transient membrane inversion, at the regions corre-
sponding to the ligand-9R binding sites, and that receptor bind-
ing by ligand-9R increases CPP concentration in a localized
manner to above the threshold required for eliciting membrane
flipping.(C) qPCR analysis of SOD-1 mRNA levels in Neuro2a cells 1 hr after treatment with RVG-9D/LR:siRNA. Erro
(D) Confocal microscopy of Neuro2a cells 30 min after incubation with RVG-9D/LR:siCy5 (red) and stained f
were stained with Hoechst 33342 (blue).
(E) Live confocal microscopy images of Neuro2a cells pretreated with cytochalasin D (Cyto D) or dynasore
plexes (green). Nuclei were stained with Hoechst 33342 (blue); 100 pmol siRNA and 10:1 peptide:siRNA we
See also Figure S3 and Movies S1, S2, S3, and S4.
Chemistry & Biology 22, 50–62, January 22, 201The L-Isoform of 9R Enables
Cytoplasmic siRNA Delivery by
RVG-9R from Endosomes
Energy-requiring mechanisms such as re-
ceptor-mediated endocytosis also
possibly contribute to cellular uptake (Fig-
ure S3A). We investigated if ligand binding
induced receptor aggregation. It is not
known which of the nAchR subunits the
RVG peptide binds. We therefore ex-
pressed the a6-subunit fused with
mCherry, which in recombinant form is
known to localize, traffic, and associate
with a4 and b2 subunits of the nAchR ex-
pressed in Neuro2A cells (Drenan et al.,
2008). Clearly, membrane assembly of
ligand-9R:siRNA complexes, generated
by adding RVG-9LR intomedium contain-
ing siFITC, aggregated membrane recep-tors evidenced by labeled nAchR receptor subunits (red) coa-
lescing with RVG-9LR:siRNA complexes (green) (Figure S4A;
see also Movie S6).
Live cell microscopy at later time points after transfection
revealed siRNA (green) in the cytoplasm as well as in
LysoTracker-positive (red) endocytic vesicles, indicating that
RVG-9R-siRNA complexes also get endocytosed and traffic
within vesicles that mature into late endosomes (Figure 5A).r bars indicate SEM.
or the early endosome marker EEA1 (green). Nuclei
1 hr after incubation with RVG-9D/LR:siFITC com-
re used in all cases.
5 ª2015 Elsevier Ltd All rights reserved 55
Figure 5. Ligand-9LR Enables siRNA Release from Endosomes, Prolonging mRNA Knockdown
(A) Live confocal microscopy of Neuro2a cells prestained with LysoTracker (red) at 4, 12, and 24 hr after exposure to RVG9D/LR:siFITC (green).
(B) Neuro2a cells overexpressing wild-type (WT) or dominant-negative (S34N, T22N) Rab5- or Rab7-GFP (green) were analyzed 24 hr after exposure to RVG-9D/
LR:siCy5 (red). Nuclei are stained with Hoechst 33342 (blue).
(C) qPCR analysis of SOD-1 mRNA levels in Neuro2a cells treated with RVG-9D/LR:siSOD1 at the indicated times after transfection.
(D) qPCR analysis of CD4 mRNA levels in Jurkat cells treated with scFvCD7-9D/LR:siCD4 at the indicated times after transfection.
In all cases, 100 pmol siRNA and 10:1 peptide:siRNA were used except in (D), where siRNA amounts equaled 200 pmol. LMN, Lipofectamine 2000; siLuc, siRNA
targeting firefly luciferase. (C and D) Error bars indicate SEM, *p < 0.05, **p < 0.01. See also Figure S4 and Movie S6.
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reports of cytoplasm to nuclear transport of 9R (Zaro et al.,
2009). 9D/LR:siRNA complexes were also endocytosed but
completely resident within vesicles at these times (Figure S4B)
accounting for the uptake but insignificant target mRNA knock-
down observed in Figure 1. At 24 hr, RVG-9DR:siRNA-treated
cells had a markedly punctate fluorescence distribution with
increased ‘‘arrest’’ of green siRNA within late endosomal com-
partments with little/no cytoplasmic staining (Figure 5A). On the
other hand, prominent cytoplasmic fluorescence was still evident
in RVG-9LR:siRNA-transfected cells. Image analysis revealed
cytoplasmic siRNA in approximately 40% of RVG-9LR-trans-
fected cells in contrast to <10% of RVG-9DR-treated cells at
24 hr (Figure S4C).
These data suggested that siRNA release continues to occur
after endosome maturation from intracellular vesicles with
RVG-9LR:siRNA. To explore this, we expressed GFP-reporter-
tagged wild-type and dominant-mutant Rab GTPases, Rab5
S34N and Rab7 T22N, which block early and late endosome
maturation (Barbieri et al., 2000; Feng et al., 1995). Expression
of the mutant GFP-Rab proteins did not alter the dominantly en-
dosomal localization of siRNA (red) at 24 hr in Neuro2a cells
treated with RVG-9DR:siCy5 (Figures 5B and S4D). On the other
hand, in RVG-9LR:siCy5-exposed cells, inhibition of endosomal
maturation resulted in an almost complete accumulation of red
fluorescence within vesicles and a marked reduction in cyto-
plasmic fluorescence when compared with cells expressing
wild-type Rab5 or Rab7. Thus, whereas cytoplasmic siRNA de-
livery by RVG-9DR is restricted to a limited time early after trans-
fection by the membrane-flipping mechanisms, RVG-9D/
LR:siRNA extends siRNA release from endosomes, and vesicle
maturation actively contributes to this.
We carried out a temporal analysis of gene knockdown in Neu-
ro2a cells to determine if the clear-cut differences in cytoplasmic
siRNA fluorescence with the two RVG-9R peptides at later time
points after transfection were reflected in siRNA bioactivity.
RVG-9R:siSOD1 effectively reduced target mRNA levels
(SOD-1) for up to 24 hr, and a marginally higher knockdown
was elicited with RVG-9LR:siRNA (Figure 5C). Whereas cells
treated with RVG-9DR:siSOD1 began to re-accumulate SOD-1
mRNA at 36 hr, significant knockdown persisted in RVG-9LR:
siSOD1-treated cells in accordance with the persisting cyto-
plasmic siRNA fluorescence at 24 hr (Figure 5B). siRNA effects
ceased by approximately 96 hr, given the rapid doubling time
of Neuro2A cells (0.8 day), which governs intracellular siRNA
concentration and thus duration of gene silencing (Bartlett and
Davis, 2006). A similarly prolonged silencing activity to beyond
36 hr was also noted with scFvCD7-9LR-delivered siCD4 in
Jurkat cells, whereas mRNA knockdown with scFvCD7-9DR:
siCD4 was short-lived (Figure 5D). Thus, although early siRNA
translocation depends on both ligand and CPP functions, the
CPP, through its stereochemistry, critically influences siRNA
release from late endosomes.
siRNA Release from Endosomes Depends on Proteolytic
Activity
The above observations imply that sensitivity of 9LR, but not
9DR, to late endosomal proteases may contribute to siRNA
release into the cytoplasm. siRNA complexed with the twoChemistry & Biology 22,RVG-9R peptides was stable at 37C for up to 3 hr of exposure
to RNase A in serum-free medium, whereas naked siRNA was
degraded rapidly within 30 min, demonstrating shielding of com-
plexed siRNA from nucleases (Figure 6A). However, recovery of
intact siRNA from RVG-9LR:siRNA complexes incubated in hu-
man serum containing medium was significantly reduced by
3 hr, whereas siRNA associated with RVG-9DR was intact for
as long as 24 hr (Figure 6B). This suggested that serum prote-
ase-mediated degradation of 9LR in RVG-9LR may have
exposed siRNA to serum nucleases while the protease-resistant
9DR isoform continued to protect complexed siRNA. We
explored whether a similar scenario existed in the late endo-
some. We treated Neuro2a cells with the membrane-permeable
inhibitor E-64d that blocks endosomal cysteine peptidase activ-
ity. This dramatically accumulated fluorescence in vesicles and
reduced cytoplasmic siRNA localization in RVG-9LR:siRNA-
treated cells in comparison to untreated cells at 24 hr after trans-
fection (Figures 6C and 6D). Furthermore, E-64d treatment also
selectively and significantly affected mRNA knockdown by
RVG-9LR:siRNA indicating that some level of degradation of
the 9R carrier in the late endosome may be a dominant factor
contributing to the overall efficiencies of RNAi achieved by
ligand-9LR delivery systems (Figure 6E).
Collectively, these data demonstrate that cell-binding ligands
can transform 9R peptides into effective siRNA delivery agents
by eliciting trafficking mechanisms that result in cytoplasmic de-
livery of siRNA (Figure 7).
DISCUSSION
Cationic CPPs, such as 9R, form nano-sized particles with nega-
tively charged siRNA. However, when used in this manner for
‘‘actively’’ transporting siRNA into cells, gene knockdown is
not very effective because siRNA is poorly transferred to the
cytoplasm (Endoh and Ohtsuki, 2009; Margus et al., 2012). We
investigated mechanisms whereby attachment to cell-binding li-
gands restores CPP function, transforming 9R peptides into
potent agents for siRNA delivery.
Ligand attachment to 9R increased siRNA uptake by more
than two orders of magnitude. Ligand-receptor binding was vi-
tal for uptake; however, mechanistic translocation of siRNA
critically depended on 9R. Live confocal microscopy revealed
fluorescent ligand-9R:siRNA complexes tethering as micropar-
ticles on the plasma membrane whose influx resulted in rapid
cytoplasmic distribution of siRNA fluorescence and mRNA
knockdown within 1 hr. The process had little dependence on
actin/dynamin function. Annexin V staining revealed topical
inversion of the cell membrane focused at the site of ligand-
9R:siRNA binding. These observations are strikingly consistent
with a study that found dodeca-arginine (R12) induced micro-
particle formation on cell membranes and subsequent inversion
of the lipid bilayer at these spots influxed R12 directly into the
cell cytoplasm (Hirose et al., 2012). The process was energy/
temperature-independent and not affected by cytochalasin D
or dynasore. The requirement of the ligand for 9R-induced
membrane inversion when 9R is associated with siRNA sug-
gests that tethering of the CPP in proximity to the cell surface
through receptor binding, which in turn increases CPP concen-
tration locally, is required for eliciting membrane inversion.50–62, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 57
Figure 6. Endosomal Proteolysis Is Required for siRNA Release from Late Endosomes
(A and B) Stability of RVG-9D/LR-siRNA complexes after exposure to RNase A (A) and 50% human AB serum (B) for the indicated periods of time. The bar graphs
represent corresponding band intensities estimated as arbitrary pixel units using the Image J software. Control refers to siRNA treated identically in the absence
of ligand-9R.
(C and D) Fluorescence distribution in E-64d-treated Neuro2a cells 24 hr after exposure to RVG-9D/LR:siFITC. Nuclei were stained with Hoechst 33342 (blue) and
endosomal vesicles with LysoTracker (red). Data in (D) were calculated using the Volocity software and a sample size of 50 cells.
(E) Analysis of murine SOD-1 mRNA levels in Neuro2a cells 36 hr after exposure to RVG9D/LR-siSOD1 (100 pmol siRNA, 10:1 peptide:siRNA).
(D and E) Error bars indicate SEM. **p < 0.01, ***p < 0.001.
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increased affinity for the plasma membrane, favoring the forma-
tion of multimeric particles at the cell surface (Hirose et al.,
2012). Thus, ligand attachment, in addition to mediating cell
binding, could be promoting amphiphilicity of 9R to induce
translocation through similar mechanisms.
Ligand-9R:siRNA complexes also trafficked through Rab5+
and Rab7+ endosomes. Octa-arginine (R8), at <5 mMconcentra-
tions, enters cells by macropinocytosis (Appelbaum et al., 2012)58 Chemistry & Biology 22, 50–62, January 22, 2015 ª2015 Elsevierafter binding to membrane proteoglycans and phospholipids
(Erazo-Oliveras et al., 2012; Verdurmen et al., 2011). However,
the evidence of ligand-induced receptor aggregation suggests
that the endocytic trafficking pathway elicited is a consequence
of receptor-mediated endocytosis. The nuclear siRNA fluores-
cence is also in agreement with observations that strongly endo-
cytosed CPPs, which can result from attachment to endocy-
tosed ligands, result in nuclear transport (Zaro et al., 2009).
The endocytic route also contributed to cytosolic delivery ofLtd All rights reserved
Figure 7. Scheme Illustrating the Mecha-
nism of Ligand-9R Translocation
The path taken by ligand-9R from the cell exterior
to the cytosol begins with binding of the ligand to
its cell-surface receptor. Cellular entry then pro-
ceeds by localized membrane inversion at the site
of ligand-9R microparticle binding and accumu-
lation on the plasmamembrane and/or within early
endosomes. siRNA then quickly translocates
across the membrane and diffuses in the cyto-
plasm. This pathway is the major route of cytosolic
delivery for both ligand-9D/LR:siRNA complexes.
siRNA translocation from late endosomes after
endocytosis is a second, slower, and controlled
route that results only when siRNA is complexed to
ligand-9LR. Blocking vesicle maturation or in-
hibiting endosomal proteases interferes with the
process, indicating that some level of proteolytic
degradation of the ligand-9LR carrier is required.
Late endosome to cytosol translocation could
occur by ‘‘membrane-flipping’’ or other such
mechanisms. 9D/LR complexes are not capable of
effectively engaging either route for cellular entry
unless used at very high concentrations.
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Ligands Potentiate CPP-Mediated siRNA DeliverysiRNA at later times, but only when ligand-9LR was used for de-
livery. It is possible that fluorophore released by nuclease-
degraded siRNA that has dissociated from ligand-9LR due
to protease action could have contributed to cytosolic fluores-
cence. However, prolonged mRNA knockdown indicated
functional siRNA activity in the cytosol and this was not the
case with ligand-9DR:siRNA despite its accumulation within
LysoTracker-positive late endosomes. Therefore, endosomal
sequestration, the major limiting factor for CPP-mediated siRNA
delivery, was appreciably overcome using ligand-9LR.
Our investigations into siRNA binding by RVG-9R peptides
reveal strong association and tight complex formation between
the two at low pH (Figure S4E). In addition, the ligand-
CPP:siRNA complex is no longer tethered to the membrane
and dissociated from the receptor at low pH within late endo-
somal compartments. This likely hinders membrane flipping
or other mechanisms such as ‘‘pore formation,’’ which require
multidentate hydrogen bonds between the guanidinium side
group in 9R and the negatively charged phospholipids enriched
in the intraluminal lipid bilayers of late endosomes. (Kobayashi
et al., 2001; Matsuo et al., 2004; Mishra et al., 2011; Yang et al.,
2010; Ziegler, 2008). Disruption/destabilization of ligand-
9LR:siRNA by late endosomal proteases could be requisite to
promote CPP-membrane interactions for continued release of
siRNA. In keeping with our data, substitution of R-CPPs and
oligo-L-arginines with D-amino acids, at the terminal positions,
obstructed degradation by endosomal proteases, reducing
cytoplasmic localization of CPP, bioactivity of attached cargo,
and transfection efficiencies (Abes et al., 2008; Fischer et al.,
2010; Mason et al., 2007; Verdurmen et al., 2011; Wu et al.,
2007). The association of RISC machinery components with in-
traluminal vesicles and membranes of the late endosome (Lee
et al., 2009; Saleh et al., 2006; Siomi and Siomi, 2009) also rai-
ses the possibility that ligand-9LR instability, in combination
with ionic competition for nucleic acid binding at lower pH,
may displace siRNA for direct loading onto the endosomalChemistry & Biology 22,RISC, enhancing the dynamics of RNA silencing in the
cytoplasm.
Hydrophobic components, such as stearyl and cholesteryl
groups, lipid membranes, and other agents that promote
endosomal escape, have conventionally been used to improve
cytosolic delivery of R-CPPs and their cargo (El-Sayed et al.,
2009; Endoh and Ohtsuki, 2009; Hayashi et al., 2011; Kim
et al., 2006, 2010; Nakamura et al., 2007; Nakase et al., 2004;
To¨nges et al., 2006). Our data demonstrate that attachment
of 9R and possibly other CPPs to cell-binding ligands can over-
come the key rate-limiting step of delivery to the cytosol as
depicted schematically in Figure 7. We hypothesize that
ligand-receptor binding induces localized accumulation of
microparticle-like structures on the plasma membrane, concen-
trating CPPs to a threshold level that induces siRNA transloca-
tion into the cytosol across the membrane from the exterior
and/or from endosomes. The mechanism involved is CPP-
mediated membrane flipping, which is actin/dynamin indepen-
dent when it occurs at the plasma membrane. This constitutes
the major route of cytosolic delivery. Late endosome to cytosol
is a second, more controlled route that extends the kinetics of
gene silencing through proteolytic disruption of ligand-
9LR:siRNA complexes, promoting membrane-CPP interac-
tions. 9D/LR:siRNA complexes are not capable of effectively
engaging either route for cellular entry unless used at very
high concentrations.
Because the ligand-9R strategy relies on surface receptor
expression, it can be effectively used for primary and suspension
cells independent of confluence under conditions identical to
those established in cell lines. Through the use of a ligand that
confers cell specificity, the approach has the benefit of concen-
trating siRNA activity within select cells, enabling reduced
dosing, which is key for in vivo treatment potency. Alternatively,
ligands that bind receptors onmultiple cell types, e.g., epidermal
growth factor transferrin and those of the integrin family, can
expand applicability to whole cell populations (Ming, 2011).50–62, January 22, 2015 ª2015 Elsevier Ltd All rights reserved 59
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harnessing the therapeutic potential of siRNA.
SIGNIFICANCE
Cationic cell-penetrating peptides (CPPs), such as nona-
arginine (9R), that translocate covalently attached biomole-
cules into the cellular cytoplasm poorly deliver electrostati-
cally complexed siRNA. Our study highlights the proficiency
of 9R in functional siRNA delivery when chimeric with pep-
tide and protein ligands (ligand-9R) that bind cellular recep-
tors. By correlating siRNA bioactivity with live-cell confocal
and time-lapse microscopy observations, we conclude that
ligand-9R primarily enables rapid siRNA translocation into
the cytosol through microparticles that accumulate on
cell membranes upon ligand attachment to the receptor
inducing localized topical membrane inversion. siRNA is
also released into the cytosol from late endosomes after re-
ceptor-mediated endocytosis of ligand-9R complexes, but
only with the L isoform of 9R (ligand-9LR), and is critically
dependent on endosomal protease activity. siRNA com-
plexed to ligand-9LR efficiently prolongs target gene
mRNA knockdown even in cells resilient to transfection,
such as human T cells. siRNAs are an indispensable analyt-
ical platform for biological target validation in vitro. siRNAs
have, however, been underexploited as a therapeutic plat-
form because effective siRNA delivery systems are lacking.
Our studies highlight that 9R and possibly other CPPs can
be harnessed for effective siRNA transport by routing them
to receptors using cell-binding ligands because this initiates
a pathway that synergizes cellular uptake with mechanisms
that lead to cytosolic release—a critical requirement for the
functional outcome of siRNA.
EXPERIMENTAL PROCEDURES
siRNA Transfection Experiments
9D/LR or RVG-9D/LR was incubated with siRNA (100 pmol) in serum-free
Dulbecco’s modified Eagle’s medium (DMEM) at molar ratios ranging between
5 and 25 for 20 min at room temperature and added to Neuro2a cells cultured
in DMEM-10 at final concentrations between 1 and 5 mM. Experiments with
scFvCD7-9D/LR used 5 mM protein on human Jurkat T cells. Carrier-to-siRNA
ratio was maintained at 10:1 unless otherwise mentioned. Lipofectamine 2000
(Invitrogen) was used according to manufacturer’s instructions. For inhibiting
actin/dynamin activity, Neuro2a cells were pretreated for 1 hr with 5 mM cyto-
chalasin D (Sigma) or 80 mM dynasore (Sigma). For inhibiting endosomal pro-
teases, Neuro2a cells were pretreated for 1 hr with 40 mM E-64d (Sigma) and
chased in medium containing E-64d after addition of peptide:siRNA com-
plexes. For blocking nAchR, Neuro2a cells were pretreated for 30 min on ice
with 105 M A568- labeled a-bungarotoxin prior to addition of peptide:siRNA
complexes. Mammalian expression plasmids encoding (1) wild-type Rab5,
Rab7, Rab5(S34N), and Rab7(T22N) fused in frame to eGFP; and (2) a4, b2,
and a6 (the latter fused to mCherry) subunits of the mammalian nAchR were
transfected into Neuro2a cells using Lipofectamine 2000 48 hr prior to treat-
ment with RVG-9R:siRNA complexes.
Gene silencing was analyzed by flow cytometry for reporter GFP expression
or qPCR for murine SOD1 and human CD4 mRNA levels (Kumar et al., 2007,
2008) normalizing to murine GAPDH and human beta-actin, respectively.
Confocal Microscopy
Neuro2a cells seeded and cultured in complete medium on poly-L-lysine
(Sigma-Aldrich) treated coverslips were incubated with 9D/LR-GFP (1 mM) or60 Chemistry & Biology 22, 50–62, January 22, 2015 ª2015 Elsevierpeptide:siRNA complexes (300 pmol siRNA, final concentration 3 mM, 10:1
molar ratio). Confocal microscopy was performed in most cases, without
washing or fixing, using Volocity spinning disc Nikon TE2000 confocal micro-
scope equipped with an environmental chamber (LIVE CELL; Pathology
Devices) and a Nikon Perfect Focus with a 603 Nikon objective (ND 1.4) or a
Leica TCS SP5 Spectral Confocal Microscope at 633magnification. Hoechst
33342was used to distinguish nuclei; LysoTracker Red to stain late endosomal
vesicles. For experiments depicting membrane interactions of ligand-9R:
siRNA complexes, siFITC (300 pmol, final concentration 3 mM) and/or
Alexa568-labeled annexin V was first added to Neuro2A cells followed by addi-
tion of RVG-9LR (10:1 peptide:siRNA ratio). Early endosomeswere detected in
cells fixed with 4% paraformaldehyde by staining with rabbit anti-EEA1 and
mouse anti-rabbit FITC (green) antibodies. All images were processed using
Volocity 6.2.1 software (Improvision/PerkinElmer). Quantification of image in-
tensities was performed with Image J 1.49b software.
Ribonuclease A and Serum Protection Assays
Peptide:siRNA complexes (100 pmol siRNA, 10:1 ratio) were incubated at
37C in 100 ng RNase A or 50% human AB serum (not heat inactivated) con-
tained in DMEM. Timed aliquots were treated with proteinase K (50 mg/ml,
10 min at 25C) and RNA extracted with phenol chloroform-isoamyl alcohol
(25:24:1 v/v). All samples were subjected to electrophoresis on a 2% agarose
gel with ethidium bromide. Band intensities were estimated using the Image J
software.
Statistical Analysis
Results are presented as mean ± SD or mean ± SEM as indicated. Statistical
significance was calculated using data from three independent experiments
using one-way ANOVAwith Bonferroni’s multiple-comparison test for pairwise
comparisons within groups. Otherwise, comparisons were made using a two-
tailed t test.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and six movies and can be found with this article online at
http://dx.doi.org/10.1016/j.chembiol.2014.11.009.
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